EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Emerging Effects of Glucagon‐Like Peptide‐1 Receptor Agonists and Sodium‐Glucose Cotransporter 2 Inhibitors on Male Sexual Hormones and Behaviors: Systematic Review and Meta‐Analysis

Giovanni Corona iD, Clotilde Sparano iD, Marilina Romeo iD, Giulia Rastrelli, Linda Vignozzi iD, Mario Maggi

Andrology · 2026-10 · 14 (7) · 1988-2001

DOI: 10.1111/andr.70238 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Andrology, online erschienen am 21.04.2026. Verfasst von Giovanni Corona und 5 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology and Metabolic Diseases Romagna Unit, AUSL Romagna, Forli'-Cesena, Italy. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, Hypogonadism, Sexual Dysfunction, Physiological. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 92 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The efficacy of glucagon‐like peptide‐1 receptor agonists (GLP1‐RA) and sodium‐glucose cotransporter 2 inhibitors (SGLT2i) in weight loss and long‐term cardiovascular (CV) safety is established. The role of these medications on male sexual hormones and function has not been adequately clarified.

Objective

To systematically review and meta‐analyze the effects of GLP1‐RA and SGLT2i on obesity‐associated hypogonadism and sexual dysfunctions.

Methods

A systematic search of Medline was conducted from 1969 to August 2025, according to PRISMA and MOOSE guidelines. All observational or randomized controlled trials evaluating the effects of GLP1‐RA or SGLT2i on hormonal and/or sexual parameters in overweight and obese subjects with or without diabetes mellitus (DM) were included in the analysis.

Results

Eight studies, including 375 subjects, evaluated the effects of GLP1‐RAs, whereas three, accounting for 52 subjects, investigated the effects of SGLT2is. Both classes of medications showed an overall improvement of body composition and metabolic profile, resulting in positive erectile function outcomes. Only GLP1‐RAs significantly increased total and calculated free testosterone along with gonadotropins. The findings of GLP1‐RAs on T levels were independent from the observed weight loss, suggesting a direct, rather than an indirect, mechanism of action on the hypothalamus–pituitary–testis axis. Finally, the use of testosterone replacement therapy (TRT) showed better results as compared to GLP1‐RAs when orgasm and sexual satisfaction domains were investigated.

Conclusions

Present data support the use of GLP1‐RAs for improving sexual dysfunction, and its underlying CV problems, in obese patients with ED. A combination of TRT and GLP1‐RAs can be considered in selected cases. Data on SGLT2is are too limited to draw final conclusions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsGlucagon-Like Peptide-1 Receptor AgonistsHypogonadismSexual Dysfunction, PhysiologicalHumansMaleObesityTestosteroneWeight Loss

Stichwörter der Autor:innen

GLP1‐RASGLT2ierectile dysfunctionhypogonadismobesitytestosteroneweight loss

Substanzen

Sodium-Glucose Transporter 2 InhibitorsGlucagon-Like Peptide-1 Receptor AgonistsTestosterone

Autor:innen und Institutionen

  • Endocrinology and Metabolic Diseases Romagna Unit, AUSL Romagna, Forli'-Cesena, Italy.
  • Endocrinology Unit, Mario Serio" Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.
  • Andrology, Women's Endocrinology and Gender Incongruence Unit, Mario Serio" Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.
  • Endocrinology and Diabetology Unit, Humanitas Gavazzeni Institute, Bergamo, Italy.

ORCID-Profile: Giovanni Corona, Clotilde Sparano, Marilina Romeo, Linda Vignozzi

Zitieren

APA

Corona, G., Sparano, C., Romeo, M., Rastrelli, G., Vignozzi, L., & Maggi, M. (2026). Emerging Effects of Glucagon‐Like Peptide‐1 Receptor Agonists and Sodium‐Glucose Cotransporter 2 Inhibitors on Male Sexual Hormones and Behaviors: Systematic Review and Meta‐Analysis. Andrology, 14(7), 1988-2001. https://doi.org/10.1111/andr.70238

Vancouver

Corona G, Sparano C, Romeo M, Rastrelli G, Vignozzi L, Maggi M. Emerging Effects of Glucagon‐Like Peptide‐1 Receptor Agonists and Sodium‐Glucose Cotransporter 2 Inhibitors on Male Sexual Hormones and Behaviors: Systematic Review and Meta‐Analysis. Andrology. 2026;14(7):1988-2001. doi:10.1111/andr.70238

BibTeX
@article{Corona2026,
  author = {Corona, Giovanni and Sparano, Clotilde and Romeo, Marilina and Rastrelli, Giulia and Vignozzi, Linda and Maggi, Mario},
  title = {Emerging Effects of Glucagon‐Like Peptide‐1 Receptor Agonists and Sodium‐Glucose Cotransporter 2 Inhibitors on Male Sexual Hormones and Behaviors: Systematic Review and Meta‐Analysis},
  journal = {Andrology},
  year = {2026},
  volume = {14},
  number = {7},
  pages = {1988--2001},
  doi = {10.1111/andr.70238}
}
Kostenlos starten →